U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Acemannan, an acetylated polymannose from Aloe vera, has immunomodulatory effects. Acemannan induces IL-6/-8 expression, and p50/DNA binding in gingival fibroblasts, at least partly, via a TLR5/NF-κB-dependent signaling pathway. Acemannan selectively binds with TLR5 ectodomain flagellin recognition sites. Acemannan has various medicinal properties like osteogenic, anti-inflammatory, and antibacterial, which accelerate healing of lesions. Also, acemannan is known to have antiviral and antitumor activities in vivo through activation of immune responses. It was concluded that Aloe vera has immense potential as a therapeutic agent. Acemannan induces tissue repair. Acemannan promoted skin wound healing partly through activating AKT/mTOR-mediated protein translation mechanism, which may represent an alternative therapy approach for cutaneous wound. Many research groups have demonstrated the role of acemannan in dentistry. Acemannan can be used for the treatment of oral aphthous ulceration in patients who wish to avoid the use of steroid medication. Acemannan is an effective natural bioactive substance that promotes bone growth, increases bone surface, bone volume and bone density.

Approval Year

PubMed

PubMed

TitleDatePubMed
Acemannan increases NF-κB/DNA binding and IL-6/-8 expression by selectively binding Toll-like receptor-5 in human gingival fibroblasts.
2017 Apr 1
Stimulation of Dentin Regeneration by Using Acemannan in Teeth with Lipopolysaccharide-induced Pulp Inflammation.
2017 Jul
Acemannan and Fructans from Aloe vera (Aloe barbadensis Miller) Plants as Novel Prebiotics.
2017 Nov 22
Extraction, Purification, Structural Characteristics, Biological Activities and Pharmacological Applications of Acemannan, a Polysaccharide from Aloe vera: A Review.
2019 Apr 19
Patents

Sample Use Guides

A skin patch test was performed on 100 healthy subjects, and 0.5% acemannan in Carbopol® 934P NF (Lubrizol Corporation, USA) was applied to the oral mucosa of the lower lip of 50 healthy participants 3 times/day for 7 days. Another 180 subjects with recurrent aphthous ulceration randomly received one of three treatments: 0.1% triamcinolone acetonide (HOE Pharmaceuticals, Malaysia), 0.5% acemannan in Carbopol® 934P NF, or pure Carbopol® 934P NF. Medications were applied to the ulcers 3 times/day for 7 days.
Route of Administration: Dental
Acemannan was found to possess oral wound healing functions in human gingival fibroblasts and rats, including stimulating the expression of keratinocyte growth factor‐1 (KGF‐1), vascular endothelial growth factor (VEGF) and type I collagen production in cells at a dose of 16 mg/mL
Substance Class Polymer
Created
by admin
on Fri Dec 15 19:46:17 UTC 2023
Edited
by admin
on Fri Dec 15 19:46:17 UTC 2023
Record UNII
UZ29E6L2X8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACEMANNAN
INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ACEMANNAN [USAN]
Common Name English
SNOW & SUN SPORTS GEL
Brand Name English
acemannan [INN]
Common Name English
ACEMANNAN ALOE VERA (1400000 MW)
Common Name English
ACEMANNAN [MART.]
Common Name English
ACEMANNAN [MI]
Common Name English
ACEMANNAN [VANDF]
Common Name English
Acemannan [WHO-DD]
Common Name English
CELLO GEL
Common Name English
ACEMANNAN (ALOE VERA)
Common Name English
ALOE ACETYLATED MANNAN POLYSACCHARIDE 1300 KDA MW
Common Name English
POLYMANNOACETATE
Common Name English
ACEMANNAN ALOE VERA (1300000 MW)
Common Name English
CARRISYN
Brand Name English
Code System Code Type Description
CAS
110042-95-0
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
EPA CompTox
DTXSID00149125
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
FDA UNII
UZ29E6L2X8
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
INN
6355
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
USAN
Z-37
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
MESH
C058414
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
MERCK INDEX
m1297
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
Acemannan
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
RXCUI
1426875
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY RxNorm
EVMPD
SUB33378
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
DRUG CENTRAL
2985
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
NCI_THESAURUS
C169758
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
DAILYMED
UZ29E6L2X8
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
ChEMBL
CHEMBL2106045
Created by admin on Fri Dec 15 19:46:17 UTC 2023 , Edited by admin on Fri Dec 15 19:46:17 UTC 2023
PRIMARY
Display Structure of ACEMANNAN
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
FRAGMENT Amount: UNSPECIFIED SUBSTANCE
1c94b430
(not in database)
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:WEIGHT AVERAGE(GEL PERMEATION CHROMATOGRAPHY) CHEMICAL